Abstract
Twenty-three different laboratories using four different assay methods reported zidovudine (ZDV; azidothymidine) measurements in a double-blind trial of ZDV for asymptomatic human immunodeficiency virus-infected patients (AIDS Clinical Trials Group Protocol 019). The risk of false-positive ZDV measurements was defined with coded specimens containing no ZDV in a quality control testing program. This testing identified six problem laboratories which reported ZDV levels of greater than or equal to 100 ng/ml for specimens with no ZDV; all of these laboratories used high-performance liquid chromatography. These six laboratories reported a disproportionately high fraction of positive assays for subjects randomized to the placebo group (31% for these 6 laboratories versus 4% for the other 17 laboratories; P less than 0.0001). The high number of false-positive ZDV results reported by these six laboratories suggested that many of the positive results that they reported for patient specimens were also false-positive results. This hypothesis was examined by retesting specimens from patients in the placebo group that had been reported as positive by these laboratories. Ninety percent (19 of 21) of these specimens were negative on retesting at the reference laboratory. These results confirm the hypothesis; they demonstrate the need for quality control testing to avoid the misinterpretation of multicenter trials because of incorrect laboratory data.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Curb J. D., Ford C., Hawkins C. M., Smith E. O., Zimbaldi N., Carter B., Cooper C. A coordinating center in a clinical trial: the Hypertension Detection and Followup Program. Control Clin Trials. 1983 Sep;4(3):171–186. doi: 10.1016/0197-2456(83)90001-6. [DOI] [PubMed] [Google Scholar]
- Good S. S., Reynolds D. J., de Miranda P. Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr. 1988 Sep 23;431(1):123–133. doi: 10.1016/s0378-4347(00)83075-3. [DOI] [PubMed] [Google Scholar]
- Hainline A., Jr, Miller D. T., Mather A. The Coronary Drug Project. Role and methods of the Central Laboratory. Control Clin Trials. 1983 Dec;4(4):377–387. doi: 10.1016/0197-2456(83)90023-5. [DOI] [PubMed] [Google Scholar]
- Klecker R. W., Jr, Collins J. M., Yarchoan R., Thomas R., Jenkins J. F., Broder S., Myers C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987 Apr;41(4):407–412. doi: 10.1038/clpt.1987.49. [DOI] [PubMed] [Google Scholar]
- McDougal J. S., Martin L. S., Cort S. P., Mozen M., Heldebrant C. M., Evatt B. L. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest. 1985 Aug;76(2):875–877. doi: 10.1172/JCI112045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meinert C. L., Borhani N. O., Langford H. G. Design, methods, and rationale in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials. 1989 Sep;10(3 Suppl):1S–29S. doi: 10.1016/0197-2456(89)90040-8. [DOI] [PubMed] [Google Scholar]
- Minne H. W. Quality control in parathyroid hormone radioimmunoassays: a multicentre study performed by the European Parathyroid Hormone Study Group. Eur J Clin Invest. 1984 Feb;14(1):16–23. doi: 10.1111/j.1365-2362.1984.tb00698.x. [DOI] [PubMed] [Google Scholar]
- Widdowson G. M., Kuehneman M., DuChene A. G., Hulley S. B., Cooper G. R. Quality control of biochemical data in the Multiple Risk Factor Intervention Trial: Central Laboratory. Control Clin Trials. 1986 Sep;7(3 Suppl):17S–33S. doi: 10.1016/0197-2456(86)90157-1. [DOI] [PubMed] [Google Scholar]